Abstract: A process for producing a peptide antigen conjugate suitable for administration to a mammal is disclosed. The peptide antigen conjugate comprises a peptide antigen linked to a hydrophobic block. The process comprises reacting a hydrophobic block fragment with a peptide antigen fragment comprising the peptide antigen in a pharmaceutically acceptable organic solvent in a hydrophobic block fragment to peptide antigen fragment molar ratio of 1:1 or greater under conditions to directly or indirectly link the peptide antigen to the hydrophobic block and obtaining a product solution comprising the peptide antigen conjugate, unreacted hydrophobic block fragment and pharmaceutically acceptable organic solvent.
Type:
Application
Filed:
May 22, 2019
Publication date:
April 22, 2021
Applicants:
Avidea Technologies, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Servic
Inventors:
Geoffrey Martin Lynn, Andrew Scott Ishizuka, Vincent Coble, Yaling Zhu
Abstract: The present disclosure relates to novel peptide-based vaccines, methods of manufacturing the novel peptide-based vaccines and uses thereof for delivering peptide antigens to induce an immune response, and in particular a T cell response to a subject.
Type:
Application
Filed:
April 4, 2018
Publication date:
February 20, 2020
Applicants:
Avidea Technologies, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Servic
Inventors:
Geoffrey Martin Lynn, Andrew Scott Ishizuka